Log in or Sign up for Free to view tailored content for your specialty!
Alzheimer’s Disease/Dementia News
Processed red meat intake linked to 14% higher risk for dementia
PHILADELPHIA — Individuals who consumed about two weekly servings of processed red meat had a 14% higher risk for dementia, as well as accelerated cognitive aging, vs. those who ate less than three servings a month, according to research.
Liraglutide may slow cognitive decline, brain volume loss in patients with AD dementia
PHILADELPHIA — Treatment with liraglutide appeared to reduce cognitive decline and slow volume loss in several areas of the brain after 1 year among individuals with mild to moderate Alzheimer’s dementia, according to new research.
Log in or Sign up for Free to view tailored content for your specialty!
Blood test for AD pathology demonstrates higher predictive accuracy than clinicians
PHILADELPHIA — Utilization of a specialized blood test to detect Alzheimer’s-related pathology led to higher diagnostic accuracy compared to health care professionals’ identification, data show.
Wildfire particulate exposure linked to higher odds of dementia diagnosis
PHILADELPHIA — Exposure to wildfire smoke and fine particulates was associated with increased risk of a dementia diagnosis in a cohort of older adults, data show.
Social isolation increases risk for death, dementia in older adults
Increased social isolation may be linked to greater risks for several adverse health outcomes in older adults, according to a study published in JAMA Network Open.
Study: Body composition associated with neurodegenerative disease, brain aging
Body composition patterns associated with weight and fat distribution were strongly correlated with neurodegenerative disease and brain aging, mediated by cardiovascular disease, according to research published in Neurology.
Lantheus acquires Meilleur, including global rights to PET imaging agent for Alzheimer’s
Lantheus Holdings Inc. has announced the acquisition of Meilleur Technologies Inc., which includes the transfer of its rights to an amyloid-beta positron emission tomography imaging agent.
Semaglutide does not raise risk for neurologic disorders for adults with type 2 diabetes
Semaglutide was not associated with increased risks for adverse neurologic or psychological disorders at 1 year compared with other diabetes drugs, according to data published in eClinicalMedicine.
FDA grants fast-track designation to cellular therapy for mild Alzheimer’s
The FDA has granted fast-track designation to a proprietary, scalable, allogeneic, investigational cellular therapy in development to address symptoms of mild Alzheimer’s disease, according to the manufacturer.
Q&A: Cost is largest ‘roadblock’ to lecanemab treatment for Alzheimer’s
The FDA recently approved injectable Kisunla to treat early-stage Alzheimer’s disease, joining Leqembi, which gained FDA approval in July 2023 for the same purpose.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read